Quoin Pharmaceuticals (NASDAQ:QNRX) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) released its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.15, Zacks reports.

Quoin Pharmaceuticals Stock Down 0.7 %

QNRX opened at $0.30 on Friday. The firm has a market cap of $1.49 million, a PE ratio of -0.07 and a beta of 1.82. The business has a fifty day simple moving average of $0.40 and a 200-day simple moving average of $0.56. Quoin Pharmaceuticals has a fifty-two week low of $0.27 and a fifty-two week high of $1.57.

Insider Transactions at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, COO Denise P. Carter bought 555,556 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $0.45 per share, with a total value of $250,000.20. Following the completion of the transaction, the chief operating officer now directly owns 602,648 shares in the company, valued at approximately $271,191.60. This represents a 1,179.72 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony James Culverwell bought 100,000 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, with a total value of $45,000.00. Following the transaction, the director now owns 100,317 shares of the company’s stock, valued at $45,142.65. This trade represents a 31,545.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 777,777 shares of company stock valued at $350,000 in the last three months. 3.70% of the stock is currently owned by corporate insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.